201 related articles for article (PubMed ID: 37672255)
1. Cutaneous Adverse Events and Cancer Survival Prognosis With Immune Checkpoint Inhibitor Treatment: A Systematic Review and Meta-Analysis.
Du Y; Wu W; Chen M; Dong Z; Wang F
JAMA Dermatol; 2023 Oct; 159(10):1093-1101. PubMed ID: 37672255
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
4. Management of Cutaneous Immune-Related Adverse Events in Patients With Cancer Treated With Immune Checkpoint Inhibitors: A Systematic Review.
Nadelmann ER; Yeh JE; Chen ST
JAMA Oncol; 2022 Jan; 8(1):130-138. PubMed ID: 34709352
[TBL] [Abstract][Full Text] [Related]
5. Validation of Progression-Free Survival Rate at 6 Months and Objective Response for Estimating Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-analysis.
Kok PS; Cho D; Yoon WH; Ritchie G; Marschner I; Lord S; Friedlander M; Simes J; Lee CK
JAMA Netw Open; 2020 Sep; 3(9):e2011809. PubMed ID: 32897371
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: a multi-institutional cohort study.
Zhang S; Tang K; Wan G; Nguyen N; Lu C; Ugwu-Dike P; Raval N; Seo J; Alexander NA; Jairath R; Phillipps J; Leung BW; Roster K; Chen W; Zubiri L; Boland G; Chen ST; Tsao H; Demehri S; LeBoeuf NR; Reynolds KL; Yu KH; Gusev A; Kwatra SG; Semenov YR
medRxiv; 2023 Jan; ():. PubMed ID: 36711758
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: A multi-institutional cohort study.
Zhang S; Tang K; Wan G; Nguyen N; Lu C; Ugwu-Dike P; Raval N; Seo J; Alexander NA; Jairath R; Phillipps J; Leung BW; Roster K; Chen W; Zubiri L; Boland G; Chen ST; Tsao H; Demehri S; LeBoeuf NR; Reynolds KL; Yu KH; Gusev A; Kwatra SG; Semenov YR
J Am Acad Dermatol; 2023 May; 88(5):1024-1032. PubMed ID: 36736626
[TBL] [Abstract][Full Text] [Related]
8. Patterns of Cutaneous and Noncutaneous Immune-Related Adverse Events Among Patients With Advanced Cancer.
Thompson LL; Krasnow NA; Chang MS; Yoon J; Li EB; Polyakov NJ; Molina GE; Said JT; Huang K; Kuchroo JR; Hinton AN; Reynolds KL; Chen ST
JAMA Dermatol; 2021 May; 157(5):577-582. PubMed ID: 33760001
[TBL] [Abstract][Full Text] [Related]
9. Incidence of Cutaneous Immune-Related Adverse Events and Outcomes in Immune Checkpoint Inhibitor-Containing Regimens: A Systematic Review and Meta-Analysis.
Curkovic NB; Bai K; Ye F; Johnson DB
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254829
[TBL] [Abstract][Full Text] [Related]
10. Incidence and factors associated with cutaneous immune-related adverse events to immune check point inhibitors: An ambispective cohort study.
Luangnara A; Kiratikanon S; Ketpueak T; Suksombooncharoen T; Charoentum C; Chewaskulyong B; Tovanabutra N; Chiewchanvit S; Nochaiwong S; Chuamanochan M
Front Immunol; 2022; 13():965550. PubMed ID: 36341419
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of derived neutrophil-to-lymphocyte ratio (dNLR) in patients with non-small cell lung cancer receiving immune checkpoint inhibitors: a meta-analysis.
Yang T; Hao L; Yang X; Luo C; Wang G; Lin Cai C; Qi S; Li Z
BMJ Open; 2021 Sep; 11(9):e049123. PubMed ID: 34475167
[TBL] [Abstract][Full Text] [Related]
12. Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis.
Zhou X; Yao Z; Yang H; Liang N; Zhang X; Zhang F
BMC Med; 2020 Apr; 18(1):87. PubMed ID: 32306958
[TBL] [Abstract][Full Text] [Related]
13. Effect of dermatological consultation on survival in patients with checkpoint inhibitor-associated cutaneous toxicity.
Thompson LL; Li EB; Krasnow NA; Chang MS; Said JT; Molina GE; Polyakov NJ; Yoon J; Dee EC; Huang K; Blum AE; Kuchroo JR; Hinton AN; Reynolds KL; Chen ST
Br J Dermatol; 2021 Sep; 185(3):627-635. PubMed ID: 33733456
[TBL] [Abstract][Full Text] [Related]
14. Influence of melanoma type on incidence and downstream implications of cutaneous immune-related adverse events in the setting of immune checkpoint inhibitor therapy.
Nguyen N; Wan G; Ugwu-Dike P; Alexander NA; Raval N; Zhang S; Jairath R; Phillipps J; Leung B; Roster K; Seo J; Lu C; Tang K; Choi MS; DeSimone MS; Theodosakis N; Amadife M; Cox N; Le TK; Liu F; Chen W; Bai X; Boland G; Liu D; Hurlbert MS; LeBoeuf N; Reynolds KL; Yu KH; Tsao H; Asgari M; Gusev A; Kwatra SG; Semenov YR
J Am Acad Dermatol; 2023 Jun; 88(6):1308-1316. PubMed ID: 36828138
[TBL] [Abstract][Full Text] [Related]
15. Corticosteroid administration for cancer-related indications is an unfavorable prognostic factor in solid cancer patients receiving immune checkpoint inhibitor treatment.
Wang Y; Yang M; Tao M; Liu P; Kong C; Li H; Chen Y; Yin X; Yan X
Int Immunopharmacol; 2021 Oct; 99():108031. PubMed ID: 34358857
[TBL] [Abstract][Full Text] [Related]
16. Association of proton pump inhibitor use with survival outcomes in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
Chen B; Yang C; Dragomir MP; Chi D; Chen W; Horst D; Calin GA; Li Q
Ther Adv Med Oncol; 2022; 14():17588359221111703. PubMed ID: 35860836
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta-analysis.
Ouyang Y; Liu W; Zhang N; Yang X; Li J; Long S
Cancer Med; 2021 Oct; 10(20):7021-7039. PubMed ID: 34423578
[TBL] [Abstract][Full Text] [Related]
18. Increased risk of cutaneous immune-related adverse events in patients treated with talimogene laherparepvec and immune checkpoint inhibitors: A multi-hospital cohort study.
Leung BW; Wan G; Nguyen N; Rashdan H; Zhang S; Chen W; Cohen S; Boland GM; Sullivan RJ; Fadden RM; Kaufman HL; Kwatra SG; LeBoeuf NR; Semenov YR
J Am Acad Dermatol; 2023 Jun; 88(6):1265-1270. PubMed ID: 36944564
[TBL] [Abstract][Full Text] [Related]
19. Effects of Antibiotic Use on Outcomes in Cancer Patients Treated Using Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
Yu Y; Zheng P; Gao L; Li H; Tao P; Wang D; Ding F; Shi Q; Chen H
J Immunother; 2021 Feb-Mar 01; 44(2):76-85. PubMed ID: 33208635
[TBL] [Abstract][Full Text] [Related]
20. Cancer Type and Histology Influence Cutaneous Immunotherapy Toxicities: A Multi-Institutional Cohort Study.
Wan G; Khattab S; Leung BW; Zhang S; Nguyen N; Tran M; Lin C; Chang C; Alexander N; Jairath R; Phillipps J; Tang K; Rajeh A; Zubiri L; Chen ST; Demehri S; Yu KH; Gusev A; Kwatra SG; LeBoeuf NR; Reynolds KL; Semenov YR
Br J Dermatol; 2024 Feb; ():. PubMed ID: 38366637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
